AU Patent

AU2013202513B2 — Polyethylene glycol colonic purgative composition

Assigned to Salix Pharmaceuticals Inc · Expires 2016-03-24 · 10y expired

What this patent protects

Abstract POLYETHYLENE GLYCOL COLONIC PURGATIVE COMPOSITION This invention relates to colonic purgative formulations comprising at least one polyethylene glycol and uses of these formulations. In certain embodiments of this invention, the formulation consists essentially of polyet…

USPTO Abstract

Abstract POLYETHYLENE GLYCOL COLONIC PURGATIVE COMPOSITION This invention relates to colonic purgative formulations comprising at least one polyethylene glycol and uses of these formulations. In certain embodiments of this invention, the formulation consists essentially of polyethylene glycol 8000, which aids in patient tolerance and endoscope insertion. The formulation may be administered in a variety of dosage forms including, but not limited to, a solid or liquid dosage form. In certain embodiments, the composition is useful in purging the colon completely. In other embodiments, the composition is useful as a laxative.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013202513B2
Jurisdiction
AU
Classification
—
Expires
2016-03-24
Drug substance claim
No
Drug product claim
No
Assignee
Salix Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.